logo
  

Cadence Design Systems Lifts FY22 Outlook; Shares Up 5%

While reporting its first-quarter results on Monday, Cadence Design Systems (CDNS) lifted its outlook for the full year 2022. The stock gained over 5% in extended session.

For the full year 2022, the company now expects earnings of $2.51 to $2.59 per share, adjusted earnings of $3.89 to $3.97 per share and revenues of $3.395 billion to $3.435 billion.

Previously, the company expected earnings of $2.46 to $2.56 per share, adjusted earnings of $3.70 to $3.80 per share on revenues of $3.32 billion to $3.38 billion.

Analysts polled by Thomson Reuters currently estimate earnings of $3.80 per share and revenues of $3.36 billion. Analysts' estimates typically exclude one-time items.

For the second quarter, the company expects revenues of $825 million to $845 million, earnings of $0.59 to $0.63 per share and adjusted earnings of $0.95 to $0.99 per share. Analysts currently estimate earnings of $0.92 per share and revenues of $823.74 million for the quarter.

CDNS closed Monday's trading at $151.10, up $3.03 or 2.05%, on the Nasdaq. The stock further gained $8.30 or 5.49% in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT